Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.

Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, Avogaro A

Acta diabetologica11 Jun 2013Cited by 41 (Europe PMC)

PMID23754673DOI10.1007/s00592-013-0489-3PepBankPUB-23754673

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes treated with liraglutide in routine care, HbA1c fell by a mean of 1.5% over follow-up.
In plain wordsIn adults with type 2 diabetes treated with liraglutide in routine care, HbA1c fell by about 1.5% on average.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction
Study
n = 166
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Measurements
HbA1c change
1.5%
mean reduction
Source sentences
Summary
Patients lost on average 1.5 ± 1.3 % HbA1c
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467301
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes treated with liraglutide in routine care, body weight fell by a mean of 4.0 kg over follow-up.
In plain wordsIn adults with type 2 diabetes treated with liraglutide in routine care, body weight fell by about 4 kg on average.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss
Study
n = 166
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Measurements
Weight change
4 kg
mean loss
Source sentences
Summary
1.5 ± 1.3 % HbA1c and 4.0 ± 5.0 kg body weight.
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467302
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes treated with liraglutide in routine care, 73.5% improved HbA1c and lost weight.
In plain wordsIn adults with type 2 diabetes treated with liraglutide in routine care, about three in four improved HbA1c and lost weight.
Peptide
Liraglutide
Outcome
DecreaseProportion improving both HbA1c and weight
Study
n = 166
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Measurements
Patients improving HbA1c and weight
73.5%
all patients
Source sentences
Summary
Most patients (73.5 %) improved HbA1c and loosed weight.
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467303
04HumanObservational studyOther
In adults with type 2 diabetes treated with liraglutide, a higher baseline HbA1c was independently linked to a larger HbA1c drop (r = 0.673).
In plain wordsIn adults with type 2 diabetes on liraglutide, a higher starting HbA1c was linked to a bigger HbA1c drop.
Peptide
Liraglutide
Outcome
Not applicableBaseline HbA1c as determinant of HbA1c drop
Study
n = 166
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Measurements
Correlation r
0.673 NA
baseline HbA1c and HbA1c drop
Source sentences
Summary
Significant independent determinants of HbA1c drop were baseline HbA1c (r = 0.673; p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467304
05HumanObservational studyOther
In adults with type 2 diabetes treated with liraglutide, previous insulin therapy was independently linked to a smaller HbA1c drop (r = -0.251).
In plain wordsIn adults with type 2 diabetes on liraglutide, earlier insulin use was linked to a smaller HbA1c drop.
Peptide
Liraglutide
Outcome
Not applicablePrevious insulin therapy as determinant of HbA1c drop
Study
n = 166
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Measurements
Correlation r
−0.251 NA
previous insulin therapy and HbA1c drop
Source sentences
Summary
and previous insulin therapy (r = -0.251; p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467305
06HumanObservational studyOther
In adults with type 2 diabetes treated with liraglutide, baseline BMI was the only independent determinant of weight loss (r = 0.429).
In plain wordsIn adults with type 2 diabetes on liraglutide, a higher starting BMI was linked to more weight loss.
Peptide
Liraglutide
Outcome
Not applicableBaseline BMI as determinant of weight loss
Study
n = 166
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Measurements
Correlation r
0.429 NA
baseline BMI and weight loss
Source sentences
Summary
The only independent determinant of weight loss was baseline BMI (r = 0.429; p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467306
07HumanObservational studyOther
In adults with type 2 diabetes treated with liraglutide, the HbA1c drop was unrelated to baseline BMI or to weight loss.
In plain wordsIn adults with type 2 diabetes on liraglutide, the HbA1c drop was not linked to starting BMI or to weight loss.
Peptide
Liraglutide
Outcome
No significant changeHbA1c drop in relation to baseline BMI and weight loss
Study
n = 166
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Source sentences
Summary
Drop in HbA1c was unrelated to baseline BMI or weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467307
08HumanObservational studyOther
In adults with type 2 diabetes treated with liraglutide, weight loss was unrelated to baseline HbA1c or to the HbA1c drop.
In plain wordsIn adults with type 2 diabetes on liraglutide, weight loss was not linked to starting HbA1c or to the HbA1c drop.
Peptide
Liraglutide
Outcome
No significant changeWeight loss in relation to baseline HbA1c and HbA1c drop
Study
n = 166
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · mean 9.4 months (range 4-16)As given in this study (human).
Source sentences
Summary
Weight loss was unrelated to baseline HbA1c or drop in HbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
T2D patients initiating Liraglutide therapy since September 2010 to July 2012 at 3 outpatient clinics were enrolled and followed-up.
Report a problemFND-2375467308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.